Phil Ades, MD Inaugural Endowed Professor

On December 16, 2016, Philip Ades, MD, professor of medicine, director of cardiac rehabilitation and preventive medicine, and a CVRI Distinguished Investigator, was honored as the inaugural Philip Ades, MD Professor of Cardiovascular Disease Prevention.  This professorship honors the significant impact of the cardiac rehabilitation and disease prevention work performed by Ades over his more than 30-year career at UVM.  Dedicated to improving the lives of patients with heart conditions, Ades has conducted world-class research on the important role exercise can play in rehabilitation after a heart attack and the benefits of weight loss in obese coronary heart disease patients. 

The Ades Endowed Professorship was made possible by donations from Ades and his wife, Deborah Rubin, MD, and by gifts from grateful patients, family members, and the estate of alumna Harriet Dustan '42, MD '44, a cardiologist and pioneer in the detection and treatment of hypertension. 

Click here for more information.  

Mary Cushman

Editor-In-Chief for New Journal

The International Society on Thrombosis and Haemostasis (ISTH) recently announced the launch of its new open access journal, Research and Practice in Thrombosis and Haemostasis (RPTH), naming Mary Cushman, MD, MSc, as its inaugural Editor-In-Chief. Dr. Cushman, a member of the CVRI Board of Directors, is professor of medicine in the Hematology/Oncology Division of the UVM Department of Medicine and Director of the Thrombosis and Hemostasis Program at The UVM Medical Center.

RTPH will publish a broad array of article types covering the widest possible spectrum of topics in thrombosis, hemostasis, and related areas, including studies by multidisciplinary research groups from emerging areas of research and under-represented regions of the world as well as studies and trials covering quality of care, outcomes, and dissemination and implementation science.

Click here to visit the RPTH homepage.    

Warshaw Clerkship Lecture

Pioneering Heart Failure Discovery

More than 15 years ago, David Warshaw, PhD, and coworkers discovered the precise malfunction of a specific protein in the heart that leads to hypertrophic cardiomyopathy (HCM).  An inherited disease, HCM can cause the heart to thicken and stop pumping blood effectively, leading to heart failure.  Now, a team of scientists has used some of Warshaw’s earlier findings to develop a possible therapy to prevent HCM.  Warshaw, professor and chair of molecular physiology and biophysics at UVM and a Director of CVRI, wrote about the significance of this potential therapy for a “Perspectives” column in the February 5, 2016 issue of the journal Science.  “This may offer a generalized approach to solving hypertrophic cardiomyopathy,” says Warshaw.  “I think it’s extremely promising."

Read Dr. Warshaw’s column and the report from the team of scientists.

News and Announcements

Applications for Travel Awards are now being accepted - click here for information and the application form. Your application must be received at least 30 days before the date of your presentation. 

CVRI provides internal review of grant applications to support cardiovascular research. E-mail CVRI for more information.  *NOTE: The request for internal review must be made at least 6 weeks before the submission deadline.

CVRI Annual Report

AnnRep Cover 2016

Through a summary of CVRI activities and a compilation of cardiovascular-related research and publication highlights, the CVRI Annual Report demonstrates the depth and breadth of the cardiovascular research being conducted at the University of Vermont and the UVM Medical Center. Click here to view the CVRI Annual Report for 2016.